Sign in
ANIX Stock Price, Chart, Stats & News
Anixa Biosciences, Inc.
Save
99.01M
Market cap
–
Current P/E
–
Forward P/E
ANIX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -67.67% |
ROE | -65.55% |
D/E | 0.01x |
Interest coverage ratio | – |
ANIX valuation
P/E | – |
P/S | – |
P/B | 5.62x |
P/CF | -12.32x |
P/FCF | -12.43x |
P/OCF | -12.32x |
PEG | -0.93x |
EV multiple | -7.87x |
About
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment.
Similar securities
Based on sector and market capitalization
Report issue